For years, promises of growth had been more than enough to send marijuana stock valuations higher. However, things changed when Canada legalized recreational marijuana and opened its doors to adult-use weed sales on Oct. 17, 2018. No longer are promises sufficient to send cannabis stock market caps higher. Instead, Wall Street is looking to marijuana stock operating results and allowing sales growth to do a lot of the talking.

Considering that Canada is struggling with early stage supply issues, and most recreationally legal U.S. states are battling persistent black markets because of high excise tax rates, cannabis sales growth has mostly been disappointing this year. But according to Wall Street, four pot stocks are on track to grow their top lines by a minimum of 355% next year.

A handful of cannabis buds lying atop a messy pile of cash bills.

Image source: Getty Images.

Auxly Cannabis Group: Sales growth of 3,056%

In terms of the fastest-growing cannabis stocks, there's Auxly Cannabis Group (CBWTF -8.81%) and everyone else next year. Auxly, which has more than one dozen streaming deals in place, as well as a notable joint venture with Sunens, is expected to grow sales from an estimated 5.8 million Canadian dollars in 2019 to CA$184.3 million in sales.

You're probably wondering why Auxly Cannabis will only generate CA$5.8 million in full-year sales after Canada legalized recreational marijuana. For starters, Auxly's production is expected to come from its streaming partners and its Sunens joint venture. Most of these streaming partnerships aren't yet licensed and producing, while the Sunens joint venture won't begin production until the second quarter of next year. Most of its revenue in 2019 will likely come from contract revenue via wholly owned subsidiary KGK Sciences.

The other reason is that Auxly's management team has clearly stated its intention to hold back dried flower production with the intent of transforming this product into high-margin derivatives (e.g., vapes, edibles, and concentrates). Dried flower is a relatively low-margin products, so Auxly is forgoing low-margin sales now for higher-margin derivatives later, which will begin hitting dispensary shelves in mid-December.

A cannabis leaf and a label with the word edibles written on it that's lying atop cookies and brownies.

Image source: Getty Images.

The Green Organic Dutchman: 582%

Small-cap Canadian grower Green Organic Dutchman (TGOD.F 29.19%) also has an opportunity to knock Wall Street's socks off next year. The consensus suggests that sales could surge from CA$39.1 million in 2019 to CA$227.9 million in 2020.

When fully operational, Green Organic Dutchman projects as a top-five producer in Canada, with 219,000 kilos of peak production. And like Auxly Cannabis, TGOD, as the company is known, plans to focus a lot of its attention on derivative products. It has facility space devoted to beverage and edible production, and signed a three-year extraction-services agreement not too long ago with Neptune Wellness Solutions that'll cover an aggregate of 230,000 kilos of cannabis and hemp biomass. With the company's flagship Valleyfield campus recently receiving its organic certification, and commercial production set to ramp up, it's easy to see how TGOD's sales could skyrocket next year.

Then again, it's also important to understand that TGOD was very late to the party in terms of getting its product to market, which is why its sales are set to soar so dramatically in 2020. Even with a focus on high-margin derivatives, it's still a toss-up as to whether or not this surge in sales will lead to the company's first-year of profitability.

A person holding a vial of cannabidiol oil in front of a flowering cannabis plant.

Image source: Getty Images.

HEXO: 452%

Keeping the Canadian grower theme going, Quebec-based HEXO (HEXO) stands to see its sales grow from CA$59.7 million in 2019 to CA$329.5 million in 2020. However, it should be noted that management has repeatedly suggested that CA$400 million in sales is plausible for 2020, meaning Wall Street's consensus may need to creep higher, assuming countrywide supply issues work themselves out.

As is the theme so far, HEXO is also waiting for the official launch of derivative products. HEXO has more than 600,000 square feet of facility space set aside for processing and derivative production, as well as worked out a two-year extraction agreement with Valens GroWorks that'll result in 80,000 aggregate kilos of hemp and cannabis biomass being extracted for high-quality resins and distillates that can be used for derivatives. It's worth noting that HEXO also has a joint venture with Molson Coors Brewing -- known as Truss -- that'll see infused beverage sales begin by mid-December.

This is also a company that benefits from having what could be the most lucrative marijuana supply deal in history on its books. In April 2018, HEXO signed a five-year deal to supply cannabis to its home province of Quebec with an aggregate of 200,000 kilos of weed. Inclusive of its Newstrike Brands purchase, this should work out to about 30% of the company's output through 2023 already spoken for. Suffice to say, 2020 should be a big step forward for HEXO.

An up-close view of a premium-quality flowering cannabis plant.

Image source: Getty Images.

Flowr Corp.: 356%

The fourth and final stock offering incredible sales growth next year is small-cap British Columbian grower Flowr Corp. (FLWPF). According to Wall Street, Flowr should see sales catapult from CA$23 million in 2019 to CA$104.6 million next year.

Unlike Auxly, TGOD, and HEXO, Flowr hasn't been lumped in with major growers, at least in terms of production. Flowr's focus is on its flagship Kelowna facility, which is capable of at least 50,000 kilos of output when operating at peak capacity. But unlike most growers, Flowr is focused entirely on premium and ultra-premium dried flower and derivatives at Kelowna, meaning it should face little in the way of supply or pricing issues for its product. This Kelowna campus should see a healthy bump in production next year.

Furthermore, Flowr recently acquired the 80.2% interest in Holigen that it didn't already own. Holigen's outdoor Aljustrel grow farm in Portugal spans 7 million square feet and could yield 500,000 kilos of marijuana when fully operational. Even though outdoor-grown cannabis won't meet the exceptionally high-quality standards found at Kelowna, it'll be perfect to create derivative products for Europe's medical marijuana market.

Long story short :You'd struggle to find cannabis stocks with faster-growing top lines than these four next year.